ZINC-BASED DIAGNOSTIC FOR PROSTATE CANCER

基于锌的前列腺癌诊断

• 批准号: 6486502
• 负责人: CHRISTOPHER J. FREDERICKSON
• 金额: $ 16.82万
• 依托单位: NEUROBIOTEX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6486502
• 关键词: clinical chemistry; clinical research; diagnosis design /evaluation; human tissue; male; method development; neoplasm /cancer diagnosis; prostate neoplasms; semen; zinc

DESCRIPTION(provided by applicant): We shall develop analytical tools for measuring the amount and speciation of zinc in semen; these tools will facilitate basic research and may lead to a zinc-based diagnostic kit for prostate cancer. According to the prevailing literature, semen zinc falls by 50 percent-90 percent in the early stages of prostate cancer while not changing in benign hypertrophy. If this is true, a combined measurement of semen zinc (falling in cancer) and serum PSA (rising in cancer) could provide sensitive and selective early diagnosis for prostate cancer. We envision test kits for routine testing of seminal zinc in the clinic, or even at home. Our Phase I goals are (i) develop methods and materials for measuring all the different seminal zinc pools (free, microligand-bound, protein bound, spermatozoan), (ii) establish preliminary norms for the various zinc pools in control men and (iii) measure the same parameters in samples from select prostate cancer patients. If Phase I results warrant continuation, in Phase II we will (i) prototype procedures for home/office kits for testing semen zinc, (ii) gather large-sample clinical data on zinc as a screening tool for prostate cancer (iii) develop quantitative models of the best multi-zinc pool diagnostic of cancer. PROPOSED COMMERCIAL APPLICATION: Commercial Potential: Yearly PSA testing is recommended for all men over 50, yet 40,000 men still die annually in the US alone from prostate cancer. If a zinc-based test were used along with PSA testing, the sales of the tests could be vast, and the contribution to men's health and wellness, equally vast.

描述（由申请人提供）：我们将开发用于的分析工具 测量精液中锌的数量和形态；这些工具将 促进基础研究，并可能导致基于锌的诊断套件 前列腺癌。 根据流行文献，精液锌下降了50％-90 在前列腺癌的早期阶段的百分比，同时又不改变良性 肥大。如果这是真的，则将精液的合并测量（落入 癌症）和血清PSA（癌症中升高）可以提供敏感和选择性 前列腺癌的早期诊断。我们设想用于常规测试的测试套件 诊所甚至在家中的精确锌。 我们的I阶段目标是（i）开发用于测量所有的方法和材料 不同的精确锌池（游离，微量构建，蛋白质结合， 精子），（ii）为各种锌池建立初步规范 控制男子和（iii）在SELECT中测量样品中相同的参数 前列腺癌患者。 如果I阶段结果保证持续存在，则在第二阶段，我们将（i）原型 用于测试精液锌的家庭/办公套件的程序，（ii）收集 锌的大型临床数据作为前列腺癌的筛查工具 （iii）开发最佳多锌池诊断的定量模型 癌症。 拟议的商业应用： 商业潜力：建议所有50岁以上的男性进行年度PSA测试，但仅在美国就死于前列腺癌，每年仍有40,000名男性死亡。如果将基于锌的测试与PSA测试一起使用，那么测试的销售可能会很大，并且对男性健康和健康的贡献也同样庞大。